Beijing-based China National Biotec Group (CNBG) has said early human test results for its coronavirus vaccine candidate suggested it could be safe and effective. The experimental shot induced high-level antibodies in all inoculated participants in a Phase 1/2 clinical trial involving 1,120 healthy people. It is the second vaccine candidate from the firm to show positive results in a clinical trial.
Chinese companies and researchers have been allowed to test eight vaccine candidates in humans at home and abroad, making China a major front-runner in the race to develop a shot against the virus that has killed nearly 500,000 people globally.
CNBG, affiliated to the state-owned China National Pharmaceutical Group (Sinopharm), said earlier this month that another vaccine candidate produced by its Wuhan-based unit also triggered high-level antibodies safely in clinical trial participants based on preliminary results.
A vaccine has to prove its effectiveness in “Phase 3” human test where thousands of participants are recruited in order to be cleared for sale.
CNBG said it will run a Phase 3 for its vaccine candidate in the United Arab Emirates, without specifying which shot will be tested.
See What’s Next in Tech With the Fast Forward Newsletter
Tweets From @varindiamag
Nothing to see here - yet
When they Tweet, their Tweets will show up here.
